View in EDS HTML Full Text PDF Full Text

A 3-year progress report on the implementation of LAAM in the United States.

Saved in:
Bibliographic Details
Title: A 3-year progress report on the implementation of LAAM in the United States.
Authors: Rawson, Richard A., Hasson, Albert L., Huber, Alice M., Mccann, Michael J., Ling, Walter
Source: Addiction. Apr1998, Vol. 93 Issue 4, p533-540. 8p. 2 Charts, 1 Graph.
Subjects: Methadyl acetate, United States. Food & Drug Administration
Abstract: Aims. LAAM, a long-acting opioid agonist, was approved by the US Food and Drug Administration in 1993 for use in licensed narcotic treatment programs. These programs have the exclusive authority in the United States to dispense methadone and LAAM for the treatment of opiate dependence. The purpose of this report is to describe the course of LAAM's implementation and to document some of the factors that have influenced the time course and extent of this process . Design. Narcotic treatment programs approved for LAAM use were contacted by telephone at three timepoints following the FDA approval of LAAM in 1993 . Findings. Regulatory hurdles have been the most significant factor in slowing the use of LAAM. Some clinics have enthusiastically moved LAAM into mainstream use with great success. At other clinics LAAM implementation has been impeded by staff resistance and management reluctance. Some specific clinical practices, such as provision of adequate dose levels and flexible dosing practices, appear to be associated with superior clinical response, but issues of staff and organizational attitude toward the new medication are probably the most important impediments to a more positive response . Conclusions. The tasks involved with introducing a new opiate agonist treatment into mainstream use in the United States are numerous and complex. Clinical policies, fiscal issues and regulatory factors must all be addressed. The introduction of LAAM into the treatment system provides some useful lessons as other new addiction pharmacotherapies are moved into mainstream use. [ABSTRACT FROM AUTHOR]
Copyright of Addiction is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 548968
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A 3-year progress report on the implementation of LAAM in the United States.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Rawson%2C+Richard+A%2E%22">Rawson, Richard A.</searchLink><br /><searchLink fieldCode="AR" term="%22Hasson%2C+Albert+L%2E%22">Hasson, Albert L.</searchLink><br /><searchLink fieldCode="AR" term="%22Huber%2C+Alice+M%2E%22">Huber, Alice M.</searchLink><br /><searchLink fieldCode="AR" term="%22Mccann%2C+Michael+J%2E%22">Mccann, Michael J.</searchLink><br /><searchLink fieldCode="AR" term="%22Ling%2C+Walter%22">Ling, Walter</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Addiction%22">Addiction</searchLink>. Apr1998, Vol. 93 Issue 4, p533-540. 8p. 2 Charts, 1 Graph.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Methadyl+acetate%22">Methadyl acetate</searchLink><br /><searchLink fieldCode="DE" term="%22United+States%2E+Food+%26+Drug+Administration%22">United States. Food & Drug Administration</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Aims. LAAM, a long-acting opioid agonist, was approved by the US Food and Drug Administration in 1993 for use in licensed narcotic treatment programs. These programs have the exclusive authority in the United States to dispense methadone and LAAM for the treatment of opiate dependence. The purpose of this report is to describe the course of LAAM's implementation and to document some of the factors that have influenced the time course and extent of this process . Design. Narcotic treatment programs approved for LAAM use were contacted by telephone at three timepoints following the FDA approval of LAAM in 1993 . Findings. Regulatory hurdles have been the most significant factor in slowing the use of LAAM. Some clinics have enthusiastically moved LAAM into mainstream use with great success. At other clinics LAAM implementation has been impeded by staff resistance and management reluctance. Some specific clinical practices, such as provision of adequate dose levels and flexible dosing practices, appear to be associated with superior clinical response, but issues of staff and organizational attitude toward the new medication are probably the most important impediments to a more positive response . Conclusions. The tasks involved with introducing a new opiate agonist treatment into mainstream use in the United States are numerous and complex. Clinical policies, fiscal issues and regulatory factors must all be addressed. The introduction of LAAM into the treatment system provides some useful lessons as other new addiction pharmacotherapies are moved into mainstream use. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Addiction is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=548968
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1046/j.1360-0443.1998.9345338.x
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 8
        StartPage: 533
    Subjects:
      – SubjectFull: Methadyl acetate
        Type: general
      – SubjectFull: United States. Food & Drug Administration
        Type: general
    Titles:
      – TitleFull: A 3-year progress report on the implementation of LAAM in the United States.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Rawson, Richard A.
      – PersonEntity:
          Name:
            NameFull: Hasson, Albert L.
      – PersonEntity:
          Name:
            NameFull: Huber, Alice M.
      – PersonEntity:
          Name:
            NameFull: Mccann, Michael J.
      – PersonEntity:
          Name:
            NameFull: Ling, Walter
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 04
              Text: Apr1998
              Type: published
              Y: 1998
          Identifiers:
            – Type: issn-print
              Value: 09652140
          Numbering:
            – Type: volume
              Value: 93
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: Addiction
              Type: main
ResultId 1